MiniMed™ 670G Insulin Pump System

Insulin pump technology that automatically adjusts background insulin every 5 minutes based on a body’s unique needs.*

For people with type 1 diabetes ages 7 and up.

REQUEST MORE INFORMATION

Overview

MiniMed™ 670G Insulin Pump and CGM system

  • An insulin pump combined with CGM can enable the pump to automatically*  adjust basal (background) insulin every five minutes based on  CGM readings.
  • MiniMed™ 670G system includes our newest and most advanced CGM, the Guardian™ Sensor 3 and the Guardian™ Link 3 transmitter. 
  • The MiniMed™ 670G system helps stabilize glucose levels with fewer highs and lows, so people can focus less on their diabetes and more on whatever the day brings.

BENEFITS

Here are some of the benefits people can experience when using the MiniMed™ 670G system.

Timer icon 5 minutes

INSULIN ADJUSTMENTS
EVERY 5 MINUTES§

The system automatically changes the amount of background insulin you receive based on your body’s needs.

Push Button Icon

DISCREET INSULIN DELIVERY

The system allows you to deliver insulin through a small tube that is hidden under your clothing, rather than manual injections.

Utensil Icon

EASY MEALTIME INSULIN

With the push of a button, you can give yourself insulin.

Couple on bicycles.

Live More. Worry Less.

The MiniMed™ 670G system is the world’s first hybrid closed loop system. Using SmartGuard™ technology, the MiniMed™ 670G system constantly self-adjusts to automatically help keep your patients’ glucose level in range based on how they live every day.*

This feature can help prevent highs and lows. 85% of people wearing the system reported less anxiety and worry.1 Most people also report being less concerned about long-term complications. 95% of people reported less social burden after transitioning to our system.1

Two levels of SmartGuard™ Automation for Customized Therapy

  • Auto Mode automatically adjusts basal insulin every five minutes based on the patient’s continuous glucose monitoring (CGM) readings, helping to keep sugar levels in the target range for fewer lows and highs — day and night.*†3
  • Manual Mode with the Suspend before low option proactively addresses lows and rebound highs by automatically suspending insulin before patients reach a pre-selected low glucose limit, resuming delivery when sensor glucose levels recover.2

  

GUARDIAN™ SENSOR 3

HELP KEEP GLUCOSE LEVELS IN RANGE WITH OUR MOST ADVANCED SMARTGUARD™ TECHNOLOGY

  • Our most accurate sensor with a MARD of 8.7%*,||
  • Approved for abdomen and back of arm use.
  • Easy insertion and flexible design make it comfortable for your patients to wear every day.
  • Continuously lets your patients know where their glucose levels are and see their trends.

Guardian Sensor 3 on white background

MINIMED™ 670G SYSTEM PRODUCT SPECIFICATIONS

 

Expand All

Waterproof

Waterproof pump, protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.

Sizing

Environmental Conditions

Pump Memory

Compatible Infusion Sets

Guardian™ Link 3 Transmitter

Bolus Speed Options

Bolus Programming Increments

Altitude Range

Backlight

Basal Delivery Rate Range

Guardian™ Sensor 3

CareLink™ USB

One-Press Serter

Battery and Power

Reservoir

CONTOUR®NEXT LINK 2.4 Glucose Meter

MINIMED™ 670G SYSTEM RESOURCES

pdf MiniMed™ 670G System Protocol: Interpreting CareLink™ Reports (.pdf)

Learn protocol for interpreting CareLink™ Auto Mode reports.

1.2MB

pdf MiniMed™ 670G System Protocol: Identifying Patients (.pdf)

Learn protocol for identifying patients and setting expectations.

59KB

pdf MiniMed™ 670G System Protocol: Transitioning to Hybrid Closed Loop Therapy (.pdf)

Understand protocol for transitioning patients to the MiniMed™ 670G hybrid closed loop system.

67KB

pdf Learn the Basics: Diabetes, Insulin Pump Therapy, and Carb Counting with the MiniMed™ 670G System (.pdf)

Guide to the basics of diabetes and how the body works, insulin pump therapy, and carbohydrate counting.

2.4MB

pdf The ABCs of Managing SmartGuard™ Auto Mode (.pdf)

Learn a simple approach to managing SmartGuard™ Auto Mode.

222KB

Request More Information

A representative can keep you informed about new and existing Medtronic products. For more information, please fill out the form.

* Indicates a required field.

By clicking Submit, I confirm that I have read and agree to the Authorization and permit Medtronic to use my contact information for the purposes described in the authorization. Read More.

WEBINARS    

On-demand videos offer practical tips from clinical experts for using Medtronic Diabetes therapies to help you support patients.

WATCH NOW

MEDICAL EDUCATION PROGRAMS

Engage with real-world case studies and explore special considerations for therapy management.

LEARN MORE

USER GUIDES AND MANUALS

Browse our library to find reference materials for your Medtronic Diabetes products.

VISIT LIBRARY
*

Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G system can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Based on clinical study data in pivotal trial. Individual results may vary.

Based on sensor glucose.

Approved for ages 14 and older.

§

Refers to AutoMode. Some interaction required. Individual results may vary.

||

Arm sensor insertion site, 3-4 calibrations/day. Approved for ages 14-75 years.

At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for more details. The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes. CGM readings may not be transmitted from the CGM to the pump while in water.

1

Gopalakrishnan S, Mueckler J, Fogel C. The MiniMed™ 670G hybrid closed loop system & patient reported outcomes concerning quality of life measures (n=2.S34). Poster #963-P presented at the 78th Scientific Sessions of the American Diabetes Association: 2018 June 22 26, Orlando, Florida, USA.

2

Bergenstal R, Garg S, Weinzimer S, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407-1408

3

dQ&A Patient Panel. [Q4 2016 Summary Report]. dQ&A 2017.

Important Safety Information: MiniMed™ 670G System

The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Ascensia Diabetes Care Logo

Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.